Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

EmboPore

Financiado

An injectable and programmable drug-eluting embolic device

This project aims to develop a novel platform for drug delivery and treatment for liver cancers. A first in its kind two-step acting platform is described in detail depicting an early step of drug elusion to viable tissue (in cont... ver más

30/11/2024

THE HEBREW UNIVERS...

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-11-30

ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2 Objective:Objectives:

I+D

Cerrada hace 2 años

0% 100% 100%

1 Participantes

THE HEBREW UNIVERSITY OF JER...

150.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

bioSWITCH Bioorthogonal Implantable Iontronic Switch to Temporally Con... 4M€ Cerrado

EmboSure Disruptive, drug free treatment of knee osteoarthritis using... 4M€ Cerrado

DESARROLLO DE STENTS CARDIOVASCULARES CON CAP... DESARROLLO DE STENTS CARDIOVASCULARES CON CAPACIDAD ANTIBACT... 20K€ Cerrado

CNS2023-143700 Materiales para biomedicina 200K€ Cerrado

PTQ2019-010406 Establecimiento de biomarcadores clínicos y plan de desarrol... 116K€ Cerrado

OatLive Mix and Match: One-step activation for targeted drug deliver... 150K€ Cerrado

Duración del proyecto: 20 meses Fecha Inicio: 2023-03-29
Fecha Fin: 2024-11-30

Líder del proyecto

THE HEBREW UNIVERSITY OF JERUSALEM No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto This project aims to develop a novel platform for drug delivery and treatment for liver cancers. A first in its kind two-step acting platform is described in detail depicting an early step of drug elusion to viable tissue (in contrast to acute embolism) followed by a later stage of vessel blockage to induce tissue necrosis is introduced here. Inspired by the coronary drug eluting stent concept we will introduce a novel porous degradable bead referred as EmboPore used as mini-stents that can elute drugs for predetermined time and collapse at the end of drug treatment period to embolize the tissue. This two-step concept ensures that a proper and massive drug perfusion will be performed prior to occlusion of the blood vessel that is used to induce tumor necrosis. Another important advantage of the gradual blockage is in reduction of the secreted adverse pro-cancer stress signals that occurs in the acute embolism procedure. The product is designed as biodegradable and injectable to fit the current catheters as being used in the standard clinical procedures. Such product is expected to substantially improve the relatively modest clinical outcomes of embolic devices and possibly open new indications such as metastatic liver diseases, gastrointestinal disease and more.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores